crc

AnBogen Therapeutics to Present Dual Breakthroughs for Imofinostat (ABT-301) at AACR 2026: Addressing Immunotherapy Barriers in CRC and Chemo-resistance in Pancreatic Cancer

TAIPEI, April 13, 2026 /PRNewswire/ -- AnBogen Therapeutics, a clinical-stage biotechnology company focused on precision oncology, today announced that two…

1 week ago

CRC and ADIA to deepen long-standing relationship

NEW YORK, March 12, 2026 /PRNewswire/ -- Christofferson Robb & Company ("CRC"), a leading New York and London based private…

1 month ago